Arecor Therapeutics PLC
LSE:AREC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38
86.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Arecor Therapeutics PLC
Income from Continuing Operations
Arecor Therapeutics PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Arecor Therapeutics PLC
LSE:AREC
|
Income from Continuing Operations
-ÂŁ10.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Income from Continuing Operations
-$235.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$250.7m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-ÂŁ51.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
ÂŁ19.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Income from Continuing Operations
-ÂŁ39.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-15%
|
|
Arecor Therapeutics PLC
Glance View
Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The company partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to their products under a technology licensing model. These products can be at any stage in development from early phase clinical development through to products that are already on the market. The areas of applications of the technology are biologicals, biosimilars, therapeutic vaccines and therapeutic peptides.
See Also
What is Arecor Therapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-10.2m
GBP
Based on the financial report for Dec 31, 2024, Arecor Therapeutics PLC's Income from Continuing Operations amounts to -10.2m GBP.
What is Arecor Therapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-52%
Over the last year, the Income from Continuing Operations growth was -20%. The average annual Income from Continuing Operations growth rates for Arecor Therapeutics PLC have been -18% over the past three years , -52% over the past five years .